Login
Evidence Feed
About
Conferences
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
nadunolimab (CAN04)
i
Other names:
CAN04, CAN-04, anti-il-1rap mab
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Twitter
Trials
Company:
Cantargia
Drug class:
IL1RAP inhibitor
‹
›
Associations
(1)
News
Twitter
Trials
Reset Filters
VERI cancer hierarchy
x
x
x
x
IL1RAP overexpression
Pancreatic Ductal Adenocarcinoma
IL1RAP overexpression
Pancreatic Ductal Adenocarcinoma
CAN04
Sensitive: C3 – Early Trials
AACR 2023 - 1 week (New C3)
CAN04
Sensitive
:
C3
AACR 2023 - 1wk
CAN04
Sensitive: C3 – Early Trials
AACR 2023 - 1 week
CAN04
Sensitive
:
C3
AACR 2023 - 1 week - (New C3)
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login